openPR Logo
Press release

The biopharmaceutical CROs market is projected to be worth USD 67 billion by 2030, claims Roots Analysis

07-07-2021 07:08 AM CET | Health & Medicine

Press release from: Roots Analysis

The biopharmaceutical CROs market is projected to be worth USD 67

Over past few years, pharmaceutical companies have outsourced various aspects of their R&D and clinical research processes to specialty contract research service providers, in order to remain competitive, flexible, and profitable in the industry

Roots Analysis has announced the addition of “Biopharmaceutical CROs Market, 2021-2030,” report to its list of offerings.

Given their numerous advantages, which include high specificity for intended molecular targets, ability to treat a myriad of disease indications, and patient friendly toxicity profiles, the demand for biologics is high and growing. This presents lucrative opportunities for contract research providers that offer services for this rapidly evolving class of pharmacological interventions. In fact, since 2001, over 80 new CROs have been established, offering a wide variety of cost-efficient research services and solutions to biologic developers.

To order this 235+ page report, which features 120+ figures and 110+ tables, please visit this https://www.rootsanalysis.com/reports/biopharmaceutical-cros-market.html

Key Market Insights

More than 160 players claim to offer contract research services to pharmaceutical and biotechnology companies across the world
This segment of the service industry is dominated by start-ups / small companies (2-50 employees) and mid-sized players (51-200 employees), which represent more than 70% of the contemporary CRO landscape. Close to 50% of the stakeholders are based in North America, followed by Europe and the Asia-Pacific region.

More than 45% of companies claim to offer research services for vaccines and cell therapies
On the other hand, close to 40% of CROs claim to have the required capabilities to provide antibody related research services. A number of biopharmaceutical research service providers are now offering services for niche and upcoming classes of biologics, such as Altasciences, Biocon, and Iris Pharma.

Since 2016, more than 70+ partnerships have been inked between CROs and industry stakeholders, worldwide
Interestingly, the maximum number of partnership agreements were inked in 2020, majority of which were acquisitions (34%), followed by clinical trial agreements (28%). It is worth noting that the partnership activity within this domain has increased at a CAGR of 55%, between 2016 and 2021.

Over 30 mergers and acquisitions were established in this domain, during the period 2016-2020
It was observed that majority of the deals were intercontinental (75%), involving participants from different countries. Geographical consolidation and service portfolio expansion were observed to the major key value drivers of M&A activity, followed by service portfolio consolidation (29%) and geographical expansion (26%).

For additional details, please visit
https://www.rootsanalysis.com/reports/biopharmaceutical-cros-market.html

North America and Europe are anticipated to capture 80% share (in terms of service revenues) of the market, by 2030
At present, close to 85% of the total revenues are generated from projects involving antibodies, vaccines and recombinant proteins; this trend is unlikely to change significantly in short to mid-term. It is worth mentioning that the contract research market for biologics in the Latin America is anticipated to grow at a relatively faster rate (14.9%), followed by the services market in MENA (14.5%).

To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/reports/biopharmaceutical-cros-market/request-sample.html
Key Questions Answered
Who are the key players offering contract research services for biopharmaceuticals?
Which kind of business models are commonly adopted by biopharmaceutical companies while outsourcing their R&D and clinical research operations?
What kind of partnership models are commonly adopted by stakeholders in this industry?
What are the key value drivers of the merger and acquisition activity within this domain?
How is the current and future market opportunity likely to be distributed across key market segments?
What are the anticipated future trends within the biopharmaceutical contract research services market?

The USD 67 billion (by 2030) financial opportunity within the biopharmaceutical contract research service providers market has been analyzed across the following segments:
Geography
North America
Europe
Asia-Pacific
MENA
Latin America

Therapeutic Area
Oncological Disorder
Neurological Disorder
Infectious Disorder
Autoimmune Disorder
Cardiovascular Disorder
Respiratory Disorder
Others

Biologics
Antibody
Cell Therapy
Gene Therapy
Vaccine
Recombinant Protein
Others

End-user
Small
Mid-sized
Very large / large

The research includes detailed profiles of key service providers (listed below) engaged in this domain; each profile features an overview of the company, information related to its biologics focused service portfolio, recent developments, and an informed future outlook.
Biocon
Covance
ICON
Medpace
Phamaron
PPD
PRA Health Sciences
Syneos Health
Vimta Labs
WuXi AppTec

For additional details, please visit
https://www.rootsanalysis.com/reports/biopharmaceutical-cros-market.html or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Top Selling Biologics Market, 2021-2030
2. Cell and Gene Therapy CROs Market (2nd Edition), 2021-2030
3. Biopharmaceutical Contract Manufacturing Market (4th Edition), 2030

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com

Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com

Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The biopharmaceutical CROs market is projected to be worth USD 67 billion by 2030, claims Roots Analysis here

News-ID: 2322752 • Views:

More Releases from Roots Analysis

Pharmacy Market Size to Hit USD 4.1 Tillion by 2035 | Exclusive Report by Roots Analysis
Pharmacy Market Size to Hit USD 4.1 Tillion by 2035 | Exclusive Report by Roots …
The global pharmacy market, valued at USD 2.4 trillion in 2024, is estimated to reach USD 2.5 trillion in 2025 and USD 4.1 trillion by 2035, representing a CAGR of 5% during the forecast period. The pharmacy market is broadly segmented on the basis of Market by Distribution by type of Pharmacy, Product Offered, Availability, Drug Molecule, Therapeutic Area and Key Geographical Regions. Revolutionizing pharmacy industry: unleashing the power of technological advancements.
Global targeted drug delivery device market is anticipated to reach to USD $2,153 Million by 2035 with CAGR of 19.7%
Global targeted drug delivery device market is anticipated to reach to USD $2,15 …
The prevalence of chronic diseases has increased significantly over the past few decades. Presently, around 129 million people in the US have at least one life threating chronic condition, such as heart disease, cancer, diabetes, obesity or hypertension. The global targeted drug delivery device market size is projected to grow from $427 Million in 2026 to $2,153 Million by 2035, representing a CAGR of 19.7% during the forecast period. Additionally, about
EMI shielding market Overview
EMI shielding market Overview
Owing to the increasing reliant on electronic devices, the risk of electromagnetic interference (EMI) has grown. EMI occurs when electromagnetic waves generated by one device disrupt the operation of nearby electronic systems. This interference can compromise device performance, reliability, and safety, making it a significant concern across various industries. To address this challenge, EMI shielding technologies have been developed. These involve the use of conductive or magnetic materials that either
Biomanufacturing market is anticipated to reach to $12.0 billion by 2035with CAGR of 18%
Biomanufacturing market is anticipated to reach to $12.0 billion by 2035with CAG …
Recognizing the potential of digitalization, biomanufacturers are increasingly adopting advanced platforms that enable operational excellence, enhance visibility, improve control, and synchronization across their bioprocessing operations Biomanufacturing refers to a standardized process that utilizes microorganisms and other biological systems to produce and develop biomolecules as therapeutic modalities. Traditionally, the biopharmaceutical companies have hesitated to adopt cutting-edge digital technologies, such as cloud computing, artificial intelligence (AI), machine learning and internet of things (IoT),

All 5 Releases


More Releases for CRO

Contract Research Organization (CRO) Research: China CRO market size is projecte …
QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report "Contract Research Organization (CRO)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031". Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2025-2031), this report provides a comprehensive analysis of the global Wire Drawing Dies market, including market size, share, demand, industry development status, and forecasts for the next few
Global Veterinary CRO & CDMO Market Size & Trends
According to a new market research report published by Global Market Estimates, the global veterinary CRO & CDMO market is expected to grow at a CAGR of 9.1% from 2023 to 2028. The growing awareness regarding the importance of animal health and welfare has led to increased investments in veterinary pharmaceutical research and development. This awareness is driven by the rising concern for the well-being of pets, livestock, and animals used
Global Contract Research Organization (CRO) Services Market
According to a new market research report published by Global Market Estimates, the Global Contract Research Organization (CRO) Services Market is expected to grow at a CAGR of 10.2% from 2023 to 2028. The growth of the contract research organization (CRO) Services Market is fuelled by factors including the rising preference for outsourcing clinical trials, increasing investments in research and development by pharmaceutical and biopharmaceutical companies, the growing complexities in drug
Contract Research Organization (CRO) Services Market - Efficiency, Expertise, Ex …
Newark, New Castle, USA: The "Contract Research Organization (CRO) Services Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Contract Research Organization (CRO) Services Market: https://www.growthplusreports.com/report/contract-research-organization-cro-services-market/7630 This latest report
Biopharmaceutical CMO and CRO Market
The Biopharmaceutical CMO and CRO Market crossed US$ 32.25 billion in 2022 and is expected to hit US$ 54.13 billion by 2030, recording a CAGR of 6.5% during the forecast period Pharmaceutical and biotech companies focus on R&D activities to innovate new molecules and therapeutic platforms to deal with chronic diseases and rare ailments; they also extensively invest in R&D activities to develop various therapeutic applications with strong medical and commercial
Pracedo Promote Ellie Copp To CRO
Pracedo, a Mashfrog Group company that provides Salesforce consultancy and digital transformation to charities, NGOs, and enterprise customers, promotes Ellie Copp to Chief Revenue Officer. Pracedo announced Ellie Copp as its new Chief Revenue Officer (CRO). Ellie joined Pracedo in 2019 and most recently held the position of Sales and Marketing Director. As CRO, she will continue to lead the commercial teams by overseeing all revenue-generating activities as Pracedo continues